NCT02326025View on ClinicalTrials.gov

A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma

PHASE1CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

January 22, 2015

Primary Completion Date

May 20, 2015

Study Completion Date

November 2, 2018

Conditions
Sarcoma, Soft Tissue
Interventions
DRUG

Olaratumab

Administered IV

DRUG

Doxorubicin

Administered IV

Trial Locations (6)

46202

IU Simon Cancer Center, Indianapolis

60611

Northwestern University, Chicago

63110

Washington University Medical Center, St Louis

80045

University of Colorado Cancer Center, Aurora

90095

UCLA Medical Center, Los Angeles

98109

Seattle Cancer Care Alliance, Seattle

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT02326025 - A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma | Biotech Hunter | Biotech Hunter